{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-032534","form_type":"8-K","ticker":null,"cik":"0000819050","company_name":"Fresh Tracks Therapeutics, Inc.","filed_at":"2023-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.724479+00:00","generated_at":"2026-06-10T14:14:02.886197+00:00","sec_items":["5.02","8.01","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Fresh Tracks approves dissolution; expects $5-7M distribution ($0.84-$1.17/share)","bullets":["Board approved plan to dissolve and liquidate, subject to shareholder vote in Q4 2023.","CEO Andrew Sklawer terminated without cause effective Oct 2; CFO Albert Marchio appointed CEO/CFO/sole director.","All three prior directors resign Oct 2; bylaws amended to allow one director.","Company discontinues all R&D, reduces workforce; estimates cash distribution of $5-7M total.","Special meeting planned; certificate of dissolution to follow, with Nasdaq delisting."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-032534","json":"https://secwatch.observer/filing/0001628280-23-032534.json","markdown":"https://secwatch.observer/filing/0001628280-23-032534.md","text":"https://secwatch.observer/filing/0001628280-23-032534.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/819050/000162828023032534/0001628280-23-032534-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/819050/000162828023032534/frtx-20230918.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T14:14:02.886197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2422a605e6","claim":"Vijay B. Samant resigned as Director at Fresh Tracks Therapeutics, Inc..","evidence_excerpt":"each of the members of the Board (Reginald L. Hardy, Gary A. Lyons and Vijay B. Samant) informed the Company that he will resign from the Board, effective October 2, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/819050/000162828023032534/0001628280-23-032534-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"cedb23c548","claim":"Albert N. Marchio, II was appointed as Chief Executive Officer, Chief Financial Officer, and Secretary at Fresh Tracks Therapeutics, Inc..","evidence_excerpt":"the Board appointed Albert N. Marchio, II, the Company’s current Chief Financial Officer, as the Company’s new Chief Executive Officer, Chief Financial Officer, and Secretary, as well as a director and Chairman of the Board, in each case effective October 2, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/819050/000162828023032534/0001628280-23-032534-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer, Chief Financial Officer, and Secretary"}],"fact_type":"executive_change"},{"claim_id":"d77d1a4572","claim":"Reginald L. Hardy resigned as Director at Fresh Tracks Therapeutics, Inc..","evidence_excerpt":"each of the members of the Board (Reginald L. Hardy, Gary A. Lyons and Vijay B. Samant) informed the Company that he will resign from the Board, effective October 2, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/819050/000162828023032534/0001628280-23-032534-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ddf6afa1a6","claim":"Gary A. Lyons resigned as Director at Fresh Tracks Therapeutics, Inc..","evidence_excerpt":"each of the members of the Board (Reginald L. Hardy, Gary A. Lyons and Vijay B. Samant) informed the Company that he will resign from the Board, effective October 2, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/819050/000162828023032534/0001628280-23-032534-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"f7d6f80797","claim":"Andrew D. Sklawer departed as President and Chief Executive Officer at Fresh Tracks Therapeutics, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of the Company terminated Andrew D. Sklawer, the Company’s President and Chief Executive Officer, without cause, effective October 2, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/819050/000162828023032534/0001628280-23-032534-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated without cause"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"b15c0358477e0c66d3f7de1491b1d83de1cc2919","claim":"Fresh Tracks Therapeutics, Inc.: Board adopted Amended and Restated Bylaws to decrease the minimum number of directors from three members to one member (effective 2023-09-18).","evidence_excerpt":"On September 18, 2023, the Board adopted Amended and Restated Bylaws to decrease the minimum number of directors from three members to one member.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/819050/000162828023032534/0001628280-23-032534-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-09-18"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}